Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser light may replace steroids for chronic mouth pain

NCT ID NCT07278999

Disease control Sponsor: Medical University of Silesia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares three treatments for painful mouth sores caused by oral lichen planus, a long-term inflammatory condition. Sixty adults will receive either a steroid cream (standard care) or one of two light-based therapies (photobiomodulation or photodynamic therapy) to see which heals sores best and reduces pain. The goal is to find a safer alternative to long-term steroid use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be between 20 and 70 years old. * Have histologically confirmed erosive or ulcerative oral lichen planus based on a biopsy. * Have no active aerobic bacterial infection or oral fungal infection. * Have had no treatment for OLP within the past 3 months. * Provide written informed consent. Exclusion Criteria: * Systemic diseases or conditions such as uncontrolled diabetes (random glucose ≥200 mg/dl), cardiovascular failure, or a pacemaker. * Autoimmune/connective tissue diseases such as lupus with positive ANA testing. * Current or past cancer, graft-versus-host disease, or hematologic disorders (anemia, leukemia, lymphoma, bleeding disorders, hemophilia, von Willebrand disease). * Enzymatic or metabolic disorders such as G6PD deficiency (favism) or porphyria. * Viral hepatitis A, B, or C. * Recent vaccinations (within the past 6 months). * Use of medications known to trigger lichenoid reactions, including: * Antihypertensives (beta-blockers, diuretics, ACE inhibitors, centrally acting agents). * Oral antidiabetics (sulfonylureas). * Metal-containing compounds (lithium, gold, arsenic, mercury). * NSAIDs (e.g., ibuprofen). * Antibiotics/chemotherapeutics (tetracyclines, sulfonamides). * Pregnancy or breastfeeding (including up to 6 months post-lactation). * Photosensitivity to UV light. * Smoking more than 5 cigarettes per day. * Lesions located adjacent to amalgam fillings or metal prosthetic restorations. * Any degree of dysplasia on histopathology. * Treatment for OLP within the last 3 months. * Active oral fungal or bacterial infection at screening. * Lack of consent to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Erosive lichen planus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lichen planus lichen planus, oral oral erosive lichen

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Erosive lichen planus Mucosal lesions Oral lichen planus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Periodontology and Oral Mucosa Diseases

    RECRUITING

    Zabrze, Silesian Voivodeship, 41-800, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.